Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

被引：0

作者：

Kan Yonemori

Kenji Tamura

Makoto Kodaira

Koshi Fujikawa

Tamotsu Sagawa

Taito Esaki

Tsuyoshi Shirakawa

Fumihiko Hirai

Yuki Yokoi

Toshio Kawata

Ben Hatano

Yasuo Takahashi

机构：

[1] National Cancer Center Hospital,Department of Breast and Medical Oncology

[2] National Hospital Organization Hokkaido Cancer Center,Department of Gastroenterology

[3] National Hospital Organization Kyushu Cancer Center,Department of Gastrointestinal and Medical Oncology

[4] National Hospital Organization Kyushu Cancer Center,Department of Thoracic Oncology

[5] AstraZeneca R and D,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2016年 / 78卷

关键词：

Olaparib; Poly(ADP-ribose) polymerase inhibitors; Clinical trial, Phase I; Safety; Solid tumours;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：525 / 531

页数：6

共 169 条

[1] Murai J(2012)Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 5588-5599
[2] Huang SY(2008)Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin Clin Cancer Res 14 3916-3925
[3] Das BB(2008)High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci USA 105 17079-17084
[4] Renaud A(2009)Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123-134
[5] Zhang Y(2010)Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with Lancet 376 245-251
[6] Doroshow JH(2010) or Lancet 376 235-244
[7] Ji J(2011) mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet Oncol 12 852-861
[8] Takeda S(2012)Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with J Clin Oncol 30 372-379
[9] Pommier Y(2012) or N Engl J Med 366 1382-1392
[10] Evers B(2014) mutations and advanced breast cancer: a proof-of-concept trial Lancet Oncol 15 852-861